These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8935886)

  • 1. New therapeutic agents marketed in 1995.
    Hussar DA
    Pa Med; 1996 Apr; 99(4):43-6. PubMed ID: 8935886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic agents marketed in 1993.
    Hussar DA
    Pa Med; 1994 Apr; 97(4):12-6. PubMed ID: 8008381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutic agents marketed in 1993.
    Hussar DA
    Pa Med; 1994 Jun; 97(6):22-3. PubMed ID: 8065777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic agents marketed in 1993.
    Hussar DA
    Pa Med; 1994 May; 97(5):12-7. PubMed ID: 8036027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic agents marketed in 1993.
    Hussar DA
    Pa Med; 1994 Jul; 97(7):16-8. PubMed ID: 7936695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic agents marketed in 1994.
    Hussar DA
    Pa Med; 1995 May; 98(5):35-8. PubMed ID: 7792092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
    Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patent life of antiretroviral drugs approved in the US from 1987 to 2007.
    Rodriguez-Monguio R; Seoane-Vazquez E
    AIDS Care; 2009 Jun; 21(6):760-8. PubMed ID: 19499381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009.
    Qureshi ZP; Seoane-Vazquez E; Rodriguez-Monguio R; Stevenson KB; Szeinbach SL
    Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):772-7. PubMed ID: 21574210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):80-2. PubMed ID: 17405529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences.
    Lexchin J
    Health Policy; 2006 Dec; 79(2-3):214-20. PubMed ID: 16472888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe.
    Pappas G; Ierodiakonou V; Falagas ME
    Clin Ther; 2009 Jul; 31(7):1595-603. PubMed ID: 19695409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic monoclonal antibodies: trends in development and approval in the US.
    Reichert JM
    Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs and other product choices.
    Hyman PM; Carvajal R
    Dermatol Ther; 2009; 22(3):216-24. PubMed ID: 19453345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Final rule.
    Fed Regist; 1998 Nov; 63(224):64556-88. PubMed ID: 10339052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Proposed rule.
    Fed Regist; 1998 Jun; 63(109):31143-61. PubMed ID: 10180130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Between a rock and a hard place.
    Demaria AN
    J Am Coll Cardiol; 2010 Nov; 56(21):1761-2. PubMed ID: 21070930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.